医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

High Profile Executive Jeffrey Dahlen, Ph.D., Accepts Senior Post at Aggredyne Inc.

2014年05月01日 PM01:16
このエントリーをはてなブックマークに追加

Smart Multimedia Gallery

 

Dr. Jeffrey Dahlen, Vice President of Clinical and Scientific Affairs and General Manager of Asia-Pacific Operations, Aggredyne, Inc. (Photo: Business Wire)Dr. Jeffrey Dahlen, Vice President of Clinical and Scientific Affairs and General Manager of Asia-Pacific Operations, Aggredyne, Inc. (Photo: Business Wire)

View and Share Photo

Close Window


HOUSTON

Houston-based Aggredyne, Inc., a biomedical diagnostics company widely recognized as a leader in the field of platelet function testing, has appointed Dr. Jeffrey Dahlen as Vice President of Clinical and Scientific Affairs and General Manager of Aggedyne’s Asia-Pacific operations.

Dr. Jeffrey Dahlen, Vice President of Clinical and Scientific Affairs and General Manager of Asia-Pa ...

Dr. Jeffrey Dahlen, Vice President of Clinical and Scientific Affairs and General Manager of Asia-Pacific Operations, Aggredyne, Inc. (Photo: Business Wire)

Dr. Dahlen is well known throughout the industry because of his many accomplishments achieved during 15 years of experience and service in the development and production of in-vitro diagnostics. He is especially noted for his ability to administer large clinical trials and for advancing the field of platelet function testing.

Before joining Aggredyne, Dr. Dahlen was Vice President of Medical and Scientific Affairs for Accriva Diagnostics, formed by the acquisition of Accumetrics, Inc. by International Technidyne, Inc. (ITC) in August 2013. Accumetrics had been a leader in platelet function testing.

Dr. Dahlen said he chose to join the Aggredyne team “because it is poised to become the leader in platelet function testing, a field to which I have dedicated most of my career. This field is important because many patients treated with antiplatelet medications have a poor response to their therapy and are left unprotected. Aggredyne’s AggreGuide platform is an excellent model for in-vitro platelet aggregation, and it is versatile, with potential to expand beyond platelet function testing to a full array of coagulation tests.”

“Since recently earning FDA clearance on our test platform and first assay (AggreGuideTM A-100 AA Assay for aspirin effect), we are ready to advance Aggredyne to the next level. Bringing Dr. Dahlen’s knowledge, experience, and stature to our team is a significant and validating milestone in growing Aggredyne,” said Dr. Edward Teitel, Aggredyne Chairman and CEO.

Dr. Dahlen earned a Bachelor of Science degree from the University of Illinois and a Doctor of Philosophy in Biomedical Sciences, Biochemistry & Molecular Biology from the University of New Mexico.

ABOUT AGGREDYNE

Aggredyne, Inc. (www.aggredyne.com), is a biomedical company founded in 2011 by Edward R. Teitel, MD, JD, and Robert C. Hux, CPA, to commercialize the AggreGuideTM platelet function analyzer. The AggreGuide system is an in-vitro diagnostic test that measures how sticky a patient’s platelets are and how well the patient is responding to antiplatelet medications, such as aspirin or Plavix® (clopidogrel).

SAFE HARBOR STATEMENT

This release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Statements in this release regarding Aggredyne’s business that are not historical facts are “forward-looking statements,” which involve risks and uncertainties that could cause actual results to differ materially from any future results, performance, or achievements expressed or implied by such statements.

Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20140430006724/en/

CONTACT

Aggredyne, Inc.
Robert C. Hux, 832-431-3995
rhux@aggredyne.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • PotNetwork Holdings, Inc.在注册成为SEC报告公司之后发布PCAOB经审计和审核的完整财务报表
  • PotNetwork Holdings, Inc.提交Form 10以成为美国证券交易委员会报告公司
  • レスメド初の最小接触面フルフェイスCPAPマスクAirFit F30を米国とカナダで販売開始
  • Foundation Medicine Announces Strategic Collaboration with Major Pharmaceutical Company
  • Biogen and Samsung Bioepis Announce European Launch of IMRALDI™(adalimumab), Solidifying Leadership in European Anti-TNF Market